Timing the initiation of multiple myeloma

Journal: Nature Communications

Published: 2020-04-21

DOI: 10.1038/s41467-020-15740-9

Affiliations: 22

Authors: 26

Go to article
Institutions Share
Sanger Institute Cancer, Ageing and Somatic Mutation Programme, United Kingdom (UK) 0.25
Department of Medicine, MSKCC, United States of America (USA) 0.13
IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy 0.12
Department of Oncology and Hemato-Oncology (DIPO), UNIMI, Italy 0.06
Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, DF/BWCC, United States of America (USA) 0.06
UCSF Division of Hematology and Medical Oncology, United States of America (USA) 0.04
Centre de Recherche en Cancérologie de Toulouse (CRCT), France 0.04
Institute of Human Genetics, Ulm University, Germany 0.04
August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Spain 0.03
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain 0.03
Hospital Clinic of Barcelona, Spain 0.03
Department of Epidemiology and Biostatistics, MSKCC, United States of America (USA) 0.02
Computational Oncology Service, MSKCC, United States of America (USA) 0.02
SIRIC ILIAD, France 0.02
Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), France 0.02
Department of Molecular Biotechnologies and Health Sciences, UNITO, Italy 0.02
VA Boston Healthcare System, United States of America (USA) 0.02
Department of Bioengineering (BE), UC San Diego, United States of America (USA) 0.01
Department of Cellular and Molecular Medicine (CMM), UC San Diego, United States of America (USA) 0.01
Moores Cancer Center, UC San Diego, United States of America (USA) 0.01
University Institute of Oncology of Asturias - Cajastur Social Programme (IUOPA), UniOvi, Spain 0.01
Departamento de Bioquímica y Biología Molecular (BBM), UniOvi, Spain 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER